ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, June 05, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital
Total number of voting rights
05/31/2025100,325,22989,110,384



For further information on Cellectis, please contact:
     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer,  

Attachment



EN
05/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE

Cellectis Reports Results from Shareholders Meeting Held on June 26, 2...

Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 57% of voting rights were exercised, resolutions 1 through 23 and resolutions 25 and 26 were adopted, while resolution 24 ...

 PRESS RELEASE

Résultats de l’Assemblée Générale Mixte de Cellectis du 26 juin 2025

Résultats de l’Assemblée Générale Mixte de Cellectis du 26 juin 2025 NEW YORK, 26 juin 2025 (GLOBE NEWSWIRE) -- (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d’édition de génome TALEN® pour développer de potentielles thérapies innovantes, a tenu une assemblée générale mixte ce jour à 14h30 heure de Paris à l’auditorium du site Biopark, situé au 11 rue Watt, 4ème étage, 75013 Paris, France. À l’issue de l’assemblée générale mixte, au cours de laquelle environ 57% des voix se sont exprimées, les résolutions 1 à...

 PRESS RELEASE

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights05/31/2025100,325,22989,110,384 For further information on Cellectis, please contact:      Media contacts:        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations conta...

 PRESS RELEASE

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 juin 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/05/2025100 325 22989 110 384 Pour de plus amples informations sur Cellectis, veuillez contacter :         Contacts média :         Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,   Patricia Sosa Navar...

 PRESS RELEASE

Cellectis’ Annual Shareholders General Meeting to be Held on June 26, ...

Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025 NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participation in t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch